Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 GLOBOCAN. International Agency for Research on Cancer. Cancer Fact Sheets: Colorectum (2012). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
  Google Scholar
• 2 American Cancer Society. Colorectal Cancer Facts & Figures 2014–2016. www.cancer.org/acs/groups/content/documents/…/acspc-042280.pdf.
  Google Scholar
• 3 Landreau P, Drouillard A, Launoy G et al. Incidence and survival in late liver metastases of colorectal cancer. J. Gastroenterol. Hepatol. 30(1), 82–85 (2015).
  MedlineGoogle Scholar
• 4 Simmonds PC, Primrose JN, Colquitt JL et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br. J. Cancer 94(7), 982–999 (2006).
  Medline CASGoogle Scholar
• 5 Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27(8), 1386–422 (2016). • Important guidelines.
  Medline CASGoogle Scholar
• 6 Hess K, Varadhachary G, Taylor S et al. Metastatic patterns in adenocarcinoma. Cancer 106(7), 1624–1633 (2006). • Important guidelines.
  MedlineGoogle Scholar
• 7 Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br. J. Surg. 93(4), 465–474 (2006).
  Medline CASGoogle Scholar
• 8 Hanly P, Maguire R, Hyland P et al. Examining the role of subjective and objective burden in carer health-related quality of life: the case of colorectal cancer. Support. Care Cancer 23(7), 1941–1949 (2015).
  MedlineGoogle Scholar
• 9 Kennedy A, Nag S, Salem R et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int. J. Radiat. Oncol. Biol. Phys. 68(1), 13–23 (2007).
  MedlineGoogle Scholar
• 10 Kennedy A. Radioembolization of hepatic tumors. J. Gastrointest. Oncol. 5(3), 178–189 (2014).
  MedlineGoogle Scholar
• 11 Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J. Hepatol. 56(2), 464–473 (2012).
  MedlineGoogle Scholar
• 12 SIR-Spheres^® Y-90 resin microspheres, Package insert. www.sirtex.com/media/155127/pi-ec-12.pdf.
  Google Scholar
• 13 Cohen SJ, Konski AA, Putnam S et al. Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer. Br. J. Cancer 111(2), 265–271 (2014).
  Medline CASGoogle Scholar
• 14 Peeters M. Future directions for selective internal radiation therapy in colorectal cancer. Eur. J. Cancer 10(3), 15–17 (2012). • Management of colorectal cancer and selective internal radiation therapy.
  Google Scholar
• 15 Van Hazel GA, Heinemann V, Sharma NK et al. SIRFLOX: randomized Phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J. Clin. Oncol. 34(15), 1723–31 (2016). •• Key study of radioembolization for treatment of metastatic colorectal cancer.
  Medline CASGoogle Scholar
• 16 Coldwell D, Sangro B, Wasan H et al. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am. J. Clin. Oncol. 34(3), 337–341 (2011). •• Key study of radioembolization for treatment of metastatic colorectal cancer.
  MedlineGoogle Scholar
• 17 Sangro B, Martínez-Urbistondo D, Bester L et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatology doi:10.1002/hep.29207 (2017) (Epub ahead of print).
  MedlineGoogle Scholar
• 18 Bester L, Meteling B, Pocock N et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J. Vasc. Interv. Radiol. 23(1), 96–105 (2012). •• Key study of radioembolization for treatment of metastatic colorectal cancer.
  MedlineGoogle Scholar
• 19 Cosimelli M, Golfieri R, Cagol PP et al. Multi-center Phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br. J. Cancer 103(3), 324–331 (2010). •• Key study of radioembolization for treatment of metastatic colorectal cancer.
  Medline CASGoogle Scholar
• 20 Seidensticker R, Denecke T, Kraus P et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc. Intervent. Radiol. 35(5), 1066–1073 (2012).
  MedlineGoogle Scholar
• 21 Kennedy AS, Ball D, Cohen SJ et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J. Gastrointest. Oncol. 6(2), 134–142 (2015).
  MedlineGoogle Scholar
• 22 Saxena A, Meteling B, Kapoor J et al. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann. Surg. Oncol. 22(3), 794–802 (2015).
  MedlineGoogle Scholar
• 23 Jakobs TF, Paprottka KJ, Raessler F et al. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur. Radiol. 27(1), 113–119 (2017).
  Medline CASGoogle Scholar
• 24 Lawal TO, Prajapato HJ, El-Rayes BF et al. Salvage yttrium-90 radioembolization after failed chemotherapy for colorectal cancer liver metastases. Hepatology 56(Suppl. 1), Abstract 1380 (2012).
  Google Scholar
• 25 Pennington B, Akehurst R, Wasan H et al. Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK. J. Med. Econ. 18(10), 797–804 (2015).
  Medline CASGoogle Scholar
• 26 van den Hoven A, Rosenbaum C, Elias S et al. Insights into the dose–response relationship of radioembolization with resin yttrium-90 microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J. Nucl. Med. 57(7), 1014–1019 (2016).
  Medline CASGoogle Scholar
• 27 Golfieri R, Mosconi C, Giampalma E et al. Selective transarterial radioembolization of unresectable liver-dominant colorectal cancer refractory to chemotherapy. Radiol. Med. 120(8), 767–776 (2015).
  MedlineGoogle Scholar
• 28 Sofocleous CT, Garcia AR, Pandit-Taskar N et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin. Colorectal Cancer 13(1), 27–36 (2014).
  MedlineGoogle Scholar
• 29 Benson AB 3rd, Geschwind JF, Mulcahy MF et al. Radioembolization for liver metastases: results from a prospective 151 patient multi-institutional Phase II study. Eur. J. Cancer 49(15), 3122–3130 (2014).
  Google Scholar
• 30 Tohme S, Sukato D, Nace GW et al. Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. HPB 16(12), 1110–1116 (2014).
  Google Scholar
• 31 Lahti SJ, Xing M, Zhang D et al. KRAS status as an independent prognostic factor for survival after yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastases. J. Vasc. Interv. Radiol. 26(8), 1102–1111 (2015).
  MedlineGoogle Scholar
• 32 Fendler WP, Philippe Tiega DB, Ilhan H et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J. Nucl. Med. 54(8), 1202–1208 (2013).
  Medline CASGoogle Scholar
• 33 Maleux G, Deroose C, Laenen A et al. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: technical results, clinical outcome and factors potentially influencing survival. Acta Oncol. 55(4), 1–10 (2015).
  MedlineGoogle Scholar
• 34 Sofocleous CT, Violari EG, Sotirchos VS et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin. Colorectal. Cancer 14(4), 296–305 (2015).
  MedlineGoogle Scholar
• 35 Leoni C, Mosconi E, Giampalma E et al. Response and survival after 90-Y radioembolization of colorectal liver metastases refractory to chemotherapy. Presented at: European Congress of Radiology. Vienna, Austria, 1–5 March 2012 (Poster No: C-0735).
  Google Scholar
• 36 Nace GW, Steel JL, Amesur N et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int. J. Surg. Oncol. 2011, 571261 (2011).
  MedlineGoogle Scholar
• 37 Saxena A, Bester L, Shan L et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J. Cancer. Res. Clin. Oncol. 140(4), 537–547 (2014).
  Medline CASGoogle Scholar
• 38 Rosenbaum CENM, Verkooijen HM, Lam MGEH et al. Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J. Nucl. Med. 54(11), 1890–1895 (2013).
  Medline CASGoogle Scholar
• 39 Hendlisz A, Van den Eynde M, Peeters M et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J. Clin. Oncol. 28(23), 3687–3694 (2010).
  Medline CASGoogle Scholar
• 40 Whitney R, Tatum C, Hahl M et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J. Surg. Res. 166(2), 236–240 (2011).
  MedlineGoogle Scholar
• 41 Sharma RA, Van Hazel GA, Morgan B et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J. Clin. Oncol. 25(9), 1099–1106 (2007).
  Medline CASGoogle Scholar
• 42 van Hazel GA, Pavlakis N, Goldstein D et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J. Clin. Oncol. 27(25), 4089–4095 (2009).
  Medline CASGoogle Scholar
• 43 Gray B, Van Hazel G, Hope M et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann. Oncol. 12(12), 1711–1720 (2001).
  Medline CASGoogle Scholar
• 44 Van Hazel G, Blackwell A, Anderson J et al. Randomised Phase II trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J. Surg. Oncol. 88(2), 78–85 (2004). •• Key study of radioembolization for treatment of metastatic colorectal cancer.
  Medline CASGoogle Scholar
• 45 Kosmider S, Tan TH, Yip D et al. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J. Vasc. Interv. Radiol. 22(6), 780–786 (2011). •• Key study of radioembolization for treatment of metastatic colorectal cancer.
  MedlineGoogle Scholar
• 46 Tie J, Yip D, Dowling R et al. Radioembolization and systemic chemotherapy in patients with hepatic metastases from primary colorectal cancer. Ann. Oncol. 21(Suppl. 8), Abstract 698 (2010).
  Google Scholar